Development Activity in Pulmonary Hypertension Market Accelerates with Debut of Japan’s First CTEPH Treatment

Adempas (riociguat), Japan’s first treatment for chronic thromboembolic pulmonary hypertension (CTEPH), a type of pulmonary hypertension (PH), was launched by Bayer Yakuhin in April this year. Some other companies have treatments for PH, but the development of more new drugs...read more